Ximelagatran (Exanta): alternative to warfarin?

Affiliations

Christy Vaughan. Proc (Bayl Univ Med Cent). 2005 Jan.

. 2005 Jan;18(1):76-80.

doi: 10.1080/08998280.2005.11928037.

¹ Department of Pharmacy Services, Baylor University Medical Center, Dallas, Texas 75246, USA. christyv@BaylorHealth.edu

No abstract available

Cited by

The History of mARC.
Clement B, Struwe MA. Clement B, et al. Molecules. 2023 Jun 12;28(12):4713. doi: 10.3390/molecules28124713. Molecules. 2023. PMID: 37375270 Free PMC article. Review.

1. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res. 2003;109(Suppl 1):S9–S15. - PubMed
1. Eriksson UG, Bredberg U, Gislen K, Johansson LC, Frison L, Ahnoff M, Gustafsson D. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol. 2003;59:35–43. - PubMed
1. Food and Drug Administration. Cardiovascular and Renal Drugs Advisory Committee; notice of meeting. Federal Register. 2004 (August 10);69(153):48509–48510. Available at http://www.fda.gov/OHRMS/DOCKETS/98fr/04-18166.htm; accessed October 13, 2004.
1. Wahlander K, Lapidus L, Olasson C, Thuresson A, Eriksson U, Larson G, Eriksson H. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res. 2002;107:93–99. - PubMed
1. Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, Sorensen H, Nagard S, Abrahamsson A, Bylund R. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res. 2001;101:171–181. - PubMed